Search

Your search keyword '"Escudier, Bernard"' showing total 1,696 results
Start Over Author "Escudier, Bernard"
1,696 results on '"Escudier, Bernard"'

1. Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial

Author

Billon, Emilien, Dalban, Cécile, Oudard, Stephane, Chevreau, Christine, Laguerre, Brigitte, Barthélémy, Philippe, Borchiellini, Delphine, Geoffrois, Lionnel, Negrier, Sylvie, Joly, Florence, Thiery-Vuillemin, Antoine, Gross-Goupil, Marine, Rolland, Frederic, Priou, Frank, Mahammedi, Hakim, Tantot, Florence, Escudier, Bernard, Chabaud, Sylvie, Albiges, Laurence, and Gravis, Gwenaelle

Published
2024
Full Text
View/download PDF

2. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome

Author

Derosa, Lisa, Iebba, Valerio, Silva, Carolina Alves Costa, Piccinno, Gianmarco, Wu, Guojun, Lordello, Leonardo, Routy, Bertrand, Zhao, Naisi, Thelemaque, Cassandra, Birebent, Roxanne, Marmorino, Federica, Fidelle, Marine, Messaoudene, Meriem, Thomas, Andrew Maltez, Zalcman, Gerard, Friard, Sylvie, Mazieres, Julien, Audigier-Valette, Clarisse, Sibilot, Denis Moro, Goldwasser, François, Scherpereel, Arnaud, Pegliasco, Hervé, Ghiringhelli, François, Bouchard, Nicole, Sow, Cissé, Darik, Ines, Zoppi, Silvia, Ly, Pierre, Reni, Anna, Daillère, Romain, Deutsch, Eric, Lee, Karla A., Bolte, Laura A., Björk, Johannes R., Weersma, Rinse K., Barlesi, Fabrice, Padilha, Lucas, Finzel, Ana, Isaksen, Morten L., Escudier, Bernard, Albiges, Laurence, Planchard, David, André, Fabrice, Cremolini, Chiara, Martinez, Stéphanie, Besse, Benjamin, Zhao, Liping, Segata, Nicola, Wojcik, Jérôme, Kroemer, Guido, and Zitvogel, Laurence

Published
2024
Full Text
View/download PDF

3. Partenariat patient dans un centre de lutte contre le cancer : mise en place et rôles d’un comité de patients et aidants

Author

De Jesus, Anne, Faveur, Anne, Garnier, Lydia, Servant, Claire, Le Bars, Sabrina, Cousin, Gérard, Dagorne, Patrick, De La Rocque, France, Delgrange, Stéphane, Guidy, Corinne, Manighetti, Joëlle, Roux, Raimonda, Sazy, Thérèse, Scull, Isabelle, Terrade, Catherine, Turkel, Liliane, Veret, Fabienne, Escudier, Bernard, Billard, Camélia, Rieutord, André, Khoury, Jane, and Blot, François

Published
2024
Full Text
View/download PDF

4. Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma

Author

Carril-Ajuria, Lucia, Lavaud, Pernelle, Dalban, Cecile, Negrier, Sylvie, Gravis, Gwénaëlle, Motzer, Robert J., Chevreau, Christine, Tannir, Nizar M., Oudard, Stéphane, McDermott, David F., Laguerre, Brigitte, Hammers, Hans J., Barthelemy, Philippe, Plimack, Elizabeth R., Borchiellini, Delphine, Gross-Goupil, Marine, Jiang, Ruiyun, Lee, Chung-Wei, de Silva, Heshani, Rini, Brian I., Escudier, Bernard, and Albigès, Laurence

Published
2024
Full Text
View/download PDF

5. Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study

Author

Mourey, Loïc, Rainho, Larissa Tames, Dalban, Cécile, Carril-Ajuria, Lucía, Negrier, Sylvie, Chevreau, Christine, Gravis, Gwenaëlle, Thibault, Constance, Laguerre, Brigitte, Barthelemy, Philippe, Borchiellini, Delphine, Gross-Goupil, Marine, Geoffrois, Lionnel, Rolland, Frederic, Thiery-Vuillemin, Antoine, Tantot, Florence, Chaput, Nathalie, Naigeon, Marie, Teixeira, Marcus, Escudier, Bernard, Flippot, Ronan, and Albiges, Laurence

Published
2024
Full Text
View/download PDF

7. Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study

Author

Baudry, Edwige, Naoun, Natacha, Auclin, Edouard, Saldana, Carolina, Barthelemy, Philippe, Geoffrois, Lionnel, Thibault, Constance, de Vries-Brilland, Manon, Borchiellini, Delphine, Maillet, Denis, Hirsch, Laure, Vauchier, Charles, Carril-Ajuria, Lucia, Colomba, Emeline, Bernard-Tessier, Alice, Escudier, Bernard, Flippot, Ronan, and Albigès, Laurence

Published
2023
Full Text
View/download PDF

8. Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting

Author

Patel, Anup, Ravaud, Alain, Motzer, Robert J, Pantuck, Allan J, Staehler, Michael, Escudier, Bernard, Martini, Jean-François, Lechuga, Mariajose, Lin, Xun, and George, Daniel J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Kidney Disease, Cancer, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Blood Platelets, Carcinoma, Renal Cell, Disease-Free Survival, Female, Humans, Kidney Neoplasms, Lymphocytes, Male, Middle Aged, Young Adult, adjuvant, lymphocyte, platelet, prognostic, renal cell carcinoma, sunitinib, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Aim: To examine the prognostic value of the platelet-to-lymphocyte ratio (PLR) in the adjuvant renal cell carcinoma setting. Materials & methods: Patients received adjuvant sunitinib (50 mg/day; 4 weeks on/2 weeks off) or placebo. The primary end point was disease-free survival (DFS). Results: In 609 patients, DFS was similar for baseline PLR

Published
2021

9. Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial

Author

Patel, Anup, Ravaud, Alain, Motzer, Robert J, Pantuck, Allan J, Staehler, Michael, Escudier, Bernard, Martini, Jean-François, Lechuga, Mariajose, Lin, Xun, and George, Daniel J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Kidney Disease, Rare Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Carcinoma, Renal Cell, Chemotherapy, Adjuvant, Clinical Trials, Phase III as Topic, Disease-Free Survival, Feasibility Studies, Female, Humans, Kaplan-Meier Estimate, Kidney Neoplasms, Lymphocyte Count, Lymphocytes, Male, Middle Aged, Multicenter Studies as Topic, Neoplasm Recurrence, Local, Nephrectomy, Neutrophils, Prognosis, Randomized Controlled Trials as Topic, Risk Assessment, Sunitinib, Young Adult, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeIn the S-TRAC trial, adjuvant sunitinib improved disease-free survival (DFS) compared with placebo in patients with locoregional renal cell carcinoma (RCC) at high risk of recurrence. This post hoc exploratory analysis investigated the neutrophil-to-lymphocyte ratio (NLR) for predictive and prognostic significance in the RCC adjuvant setting.Experimental designKaplan-Meier estimates and Cox proportional analyses were performed on baseline NLR and change from baseline at week 4 to assess their association with DFS. Univariate P values were two-sided and based on an unstratified log-rank test.Results609 of 615 patients had baseline NLR values; 574 patients had baseline and week 4 values. Sunitinib-treated patients with baseline NLR

Published
2020

10. Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study

Author

Velev, Maud, Dalban, Cécile, Chevreau, Christine, Gravis, Gwenaelle, Negrier, Sylvie, Laguerre, Brigitte, Gross-Goupil, Marine, Ladoire, Sylvain, Borchiellini, Delphine, Geoffrois, Lionnel, Joly, Florence, Priou, Frank, Barthelemy, Philippe, Laramas, Mathieu, Narciso, Berangère, Thiery-Vuillemin, Antoine, Berdah, Jean-François, Ferrari, Victoria, Dominique Thomas, Quentin, Mione, Cécile, Curcio, Hubert, Oudard, Stephane, Tantot, Florence, Escudier, Bernard, Chabaud, Sylvie, Albiges, Laurence, and Thibault, Constance

Published
2023
Full Text
View/download PDF

11. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status

Author

Carril-Ajuria, Lucía, Colomba, Emeline, Romero-Ferreiro, Carmen, Cerbone, Luigi, Ratta, Raffaele, Barthelemy, Philippe, Vindry, Clarisse, Fléchon, Aude, Cherifi, François, Boughalem, Elouen, Linassier, Claude, Fornarini, Giuseppe, Rebuzzi, Sara E., Gross-Goupil, Marine, Saldana, Carolina, Martin-Soberón, Maricruz, de Velasco, Guillermo, Manneh, Ray, Pernaut, Cristina, Sanchez de Torre, Ana, Flippot, Ronan, Escudier, Bernard, and Albiges, Laurence

Published
2023
Full Text
View/download PDF

12. B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors

Author

Flippot, Ronan, primary, Teixeira, Marcus, additional, Rey-Cardenas, Macarena, additional, Carril-Ajuria, Lucia, additional, Rainho, Larissa, additional, Naoun, Natacha, additional, Jouniaux, Jean-Mehdi, additional, Boselli, Lisa, additional, Naigeon, Marie, additional, Danlos, Francois-Xavier, additional, Escudier, Bernard, additional, Scoazec, Jean-Yves, additional, Cassard, Lydie, additional, Albiges, Laurence, additional, and Chaput, Nathalie, additional

Published
2024
Full Text
View/download PDF

17. Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study

Author

Rassy, Elie, Dalban, Cécile, Colomba, Emeline, Derosa, Lisa, Alves Costa Silva, Carolina, Negrier, Sylvie, Chevreau, Christine, Gravis, Gwenaelle, Oudard, Stephane, Laguerre, Brigitte, Barthelemy, Philippe, Goupil, Marine Gross, Geoffrois, Lionnel, Rolland, Frederic, Thiery-Vuillemin, Antoine, Joly, Florence, Ladoire, Sylvain, Tantot, Florence, Escudier, Bernard, and Albiges, Laurence

Published
2022
Full Text
View/download PDF

18. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

Author

Motzer, Robert J, Powles, Thomas, Burotto, Mauricio, Escudier, Bernard, Bourlon, Maria T, Shah, Amishi Y, Suárez, Cristina, Hamzaj, Alketa, Porta, Camillo, Hocking, Christopher M, Kessler, Elizabeth R, Gurney, Howard, Tomita, Yoshihiko, Bedke, Jens, Zhang, Joshua, Simsek, Burcin, Scheffold, Christian, Apolo, Andrea B, and Choueiri, Toni K

Published
2022
Full Text
View/download PDF

20. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

Author

McDermott, David F, Huseni, Mahrukh A, Atkins, Michael B, Motzer, Robert J, Rini, Brian I, Escudier, Bernard, Fong, Lawrence, Joseph, Richard W, Pal, Sumanta K, Reeves, James A, Sznol, Mario, Hainsworth, John, Rathmell, W Kimryn, Stadler, Walter M, Hutson, Thomas, Gore, Martin E, Ravaud, Alain, Bracarda, Sergio, Suárez, Cristina, Danielli, Riccardo, Gruenwald, Viktor, Choueiri, Toni K, Nickles, Dorothee, Jhunjhunwala, Suchit, Piault-Louis, Elisabeth, Thobhani, Alpa, Qiu, Jiaheng, Chen, Daniel S, Hegde, Priti S, Schiff, Christina, Fine, Gregg D, and Powles, Thomas

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Kidney Disease, Cancer, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carcinoma, Renal Cell, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Kaplan-Meier Estimate, Kidney Neoplasms, Male, Middle Aged, Mutation, Sunitinib, Treatment Outcome, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients with treatment-naive metastatic renal cell carcinoma. Co-primary endpoints were progression-free survival (PFS) in intent-to-treat and PD-L1+ populations. Intent-to-treat PFS hazard ratios for atezolizumab + bevacizumab or atezolizumab monotherapy versus sunitinib were 1.0 (95% confidence interval (CI), 0.69-1.45) and 1.19 (95% CI, 0.82-1.71), respectively; PD-L1+ PFS hazard ratios were 0.64 (95% CI, 0.38-1.08) and 1.03 (95% CI, 0.63-1.67), respectively. Exploratory biomarker analyses indicated that tumor mutation and neoantigen burden were not associated with PFS. Angiogenesis, T-effector/IFN-γ response, and myeloid inflammatory gene expression signatures were strongly and differentially associated with PFS within and across the treatments. These molecular profiles suggest that prediction of outcomes with anti-VEGF and immunotherapy may be possible and offer mechanistic insights into how blocking VEGF may overcome resistance to immune checkpoint blockade.

Published
2018

21. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results

Author

Motzer, Robert J, Ravaud, Alain, Patard, Jean-Jacques, Pandha, Hardev S, George, Daniel J, Patel, Anup, Chang, Yen-Hwa, Escudier, Bernard, Donskov, Frede, Magheli, Ahmed, Carteni, Giacomo, Laguerre, Brigitte, Tomczak, Piotr, Breza, Jan, Gerletti, Paola, Lechuga, Mariajose, Lin, Xun, Casey, Michelle, Serfass, Lucile, Pantuck, Allan J, and Staehler, Michael

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Kidney Disease, Clinical Trials and Supportive Activities, Clinical Research, Cancer, Genetics, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Angiogenesis Inhibitors, Carcinoma, Renal Cell, Chemotherapy, Adjuvant, Disease-Free Survival, Female, Humans, Indoles, Kaplan-Meier Estimate, Kidney Neoplasms, Male, Middle Aged, Nephrectomy, Proportional Hazards Models, Pyrroles, Risk Factors, Sunitinib, Time Factors, Treatment Outcome, Adjuvant, Disease-free survival, Renal cell carcinoma, Urology & Nephrology, Clinical sciences
Abstract

BackgroundAdjuvant sunitinib significantly improved disease-free survival (DFS) versus placebo in patients with locoregional renal cell carcinoma (RCC) at high risk of recurrence after nephrectomy (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.59-0.98; p=0.03).ObjectiveTo report the relationship between baseline factors and DFS, pattern of recurrence, and updated overall survival (OS).Design, setting, and participantsData for 615 patients randomized to sunitinib (n=309) or placebo (n=306) in the S-TRAC trial.Outcome measurements and statistical analysisSubgroup DFS analyses by baseline risk factors were conducted using a Cox proportional hazards model. Baseline risk factors included: modified University of California Los Angeles integrated staging system criteria, age, gender, Eastern Cooperative Oncology Group performance status (ECOG PS), weight, neutrophil-to-lymphocyte ratio (NLR), and Fuhrman grade.Results and limitationsOf 615 patients, 97 and 122 in the sunitinib and placebo arms developed metastatic disease, with the most common sites of distant recurrence being lung (40 and 49), lymph node (21 and 26), and liver (11 and 14), respectively. A benefit of adjuvant sunitinib over placebo was observed across subgroups, including: higher risk (T3, no or undetermined nodal involvement, Fuhrman grade ≥2, ECOG PS ≥1, T4 and/or nodal involvement; hazard ratio [HR] 0.74, 95% confidence interval [CI] 0.55-0.99; p=0.04), NLR ≤3 (HR 0.72, 95% CI 0.54-0.95; p=0.02), and Fuhrman grade 3/4 (HR 0.73, 95% CI 0.55-0.98; p=0.04). All subgroup analyses were exploratory, and no adjustments for multiplicity were made. Median OS was not reached in either arm (HR 0.92, 95% CI 0.66-1.28; p=0.6); 67 and 74 patients died in the sunitinib and placebo arms, respectively.ConclusionsA benefit of adjuvant sunitinib over placebo was observed across subgroups. The results are consistent with the primary analysis, which showed a benefit for adjuvant sunitinib in patients at high risk of recurrent RCC after nephrectomy.Patient summaryMost subgroups of patients at high risk of recurrent renal cell carcinoma after nephrectomy experienced a clinical benefit with adjuvant sunitinib.Trial registrationClinicalTrials.gov NCT00375674.

Published
2018

22. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial

Author

Beckermann, Kathryn E, primary, Asnis-Alibozek, Aviva G, additional, Atkins, Michael B, additional, Escudier, Bernard, additional, Hutson, Thomas E, additional, Kasturi, Vijay, additional, McDermott, David F, additional, Pal, Sumanta K, additional, Porta, Camillo, additional, Rini, Brian I, additional, and Verzoni, Elena, additional

Published
2024
Full Text
View/download PDF

24. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Author

Choueiri, Toni K, Fishman, Mayer N, Escudier, Bernard, McDermott, David F, Drake, Charles G, Kluger, Harriet, Stadler, Walter M, Perez-Gracia, Jose Luis, McNeel, Douglas G, Curti, Brendan, Harrison, Michael R, Plimack, Elizabeth R, Appleman, Leonard, Fong, Lawrence, Albiges, Laurence, Cohen, Lewis, Young, Tina C, Chasalow, Scott D, Ross-Macdonald, Petra, Srivastava, Shivani, Jure-Kunkel, Maria, Kurland, John F, Simon, Jason S, and Sznol, Mario

Subjects
Rare Diseases, Kidney Disease, Clinical Trials and Supportive Activities, Clinical Research, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Antibodies, Monoclonal, Antineoplastic Agents, B7-H1 Antigen, Carcinoma, Renal Cell, Chemokine CXCL10, Chemokine CXCL9, Everolimus, Female, Humans, Immunologic Factors, Interferon-gamma, Kidney Neoplasms, Lymphocytes, Male, Middle Aged, Nivolumab, Prospective Studies, Tumor Microenvironment, Up-Regulation, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeNivolumab, an anti-PD-1 immune checkpoint inhibitor, improved overall survival versus everolimus in a phase 3 trial of previously treated patients with metastatic renal cell carcinoma (mRCC). We investigated immunomodulatory activity of nivolumab in a hypothesis-generating prospective mRCC trial.Experimental designNivolumab was administered intravenously every 3 weeks at 0.3, 2, or 10 mg/kg to previously treated patients and 10 mg/kg to treatment-naïve patients with mRCC. Baseline and on-treatment biopsies and blood were obtained. Clinical activity, tumor-associated lymphocytes, PD-L1 expression (Dako immunohistochemistry; ≥5% vs.

Published
2016

27. Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma

Author

de Vries-Brilland, Manon, primary, Rioux-Leclercq, Nathalie, additional, Meylan, Maxime, additional, Dauvé, Jonathan, additional, Passot, Christophe, additional, Spirina-Menand, Elena, additional, Flippot, Ronan, additional, Fromont, Gaëlle, additional, Gravis, Gwenaelle, additional, Geoffrois, Lionnel, additional, Chevreau, Christine, additional, Rolland, Fréderic, additional, Blanc, Ellen, additional, Lefort, Félix, additional, Ravaud, Alain, additional, Gross-Goupil, Marine, additional, Escudier, Bernard, additional, Negrier, Sylvie, additional, and Albiges, Laurence, additional

Published
2023
Full Text
View/download PDF

30. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Author

Motzer, Robert J, Rini, Brian I, McDermott, David F, Arén Frontera, Osvaldo, Hammers, Hans J, Carducci, Michael A, Salman, Pamela, Escudier, Bernard, Beuselinck, Benoit, Amin, Asim, Porta, Camillo, George, Saby, Neiman, Victoria, Bracarda, Sergio, Tykodi, Scott S, Barthélémy, Philippe, Leibowitz-Amit, Raya, Plimack, Elizabeth R, Oosting, Sjoukje F, Redman, Bruce, Melichar, Bohuslav, Powles, Thomas, Nathan, Paul, Oudard, Stéphane, Pook, David, Choueiri, Toni K, Donskov, Frede, Grimm, Marc-Oliver, Gurney, Howard, Heng, Daniel Y C, Kollmannsberger, Christian K, Harrison, Michael R, Tomita, Yoshihiko, Duran, Ignacio, Grünwald, Viktor, McHenry, M Brent, Mekan, Sabeen, and Tannir, Nizar M

Published
2019
Full Text
View/download PDF

36. Progression‐free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma

Author

Halabi, Susan, Rini, Brian, Escudier, Bernard, Stadler, Walter M, and Small, Eric J

Subjects
Clinical Research, Cancer, Kidney Disease, Clinical Trials and Supportive Activities, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carcinoma, Renal Cell, Clinical Trials, Phase III as Topic, Disease-Free Survival, Endpoint Determination, Female, Humans, Interferon-alpha, Kidney Neoplasms, Male, Middle Aged, Multivariate Analysis, Neoplasm Metastasis, Proportional Hazards Models, Prospective Studies, Randomized Controlled Trials as Topic, Survival Analysis, renal cancer, surrogate, clinical trials, progression-free survival, overall survival, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundThe current study was conducted to investigate the dependence between progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) and to explore whether PFS can be used as an intermediate endpoint of OS in this patient population.MethodsA total of 1381 patients from 2 prospective phase 3 trials (Cancer and Leukemia Group B [CALGB] 90206 and AVOREN) of interferon-alpha with or without bevacizumab were analyzed. Both trials recruited previously untreated patients with clear cell mRCC with an Eastern Cooperative Oncology Group performance status of 0 to 2; adequate bone marrow, hepatic, cardiac, and renal function; and controlled blood pressure. The CALGB study served as the training data set, and the AVOREN study served as the testing data set. The dependence between PFS and OS was investigated using the Kendall tau for bivariate time-to-event endpoints.ResultsIn the training data set, the median OS times among patients who experienced progressive disease at 3 months or 6 months were 6 months and 8 months, respectively, compared with 25 months and 30 months, respectively, (P < .001) in patients who did not develop disease progress. The adjusted hazard ratios (HR) were 2.6 (P < .0001) and 2.8 (P < .0001), respectively, for patients who did and did not progress at 3 months or 6 months. The dependence between PFS and OS was 0.53. These associations were confirmed in the testing data set.ConclusionsIn patients with mRCC who were treated with interferon-alpha with or without bevacizumab, the PFS at 3 months and 6 months was found to be predictive of OS. A high dependence between PFS and OS was observed, suggesting that PFS may be used as a surrogate endpoint for OS. Although this is a novel observation for RCC, these findings require validation in patients with mRCC who are treated with other targeted agents.

Published
2014

37. Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.

Author

Tannir, Nizar M., Escudier, Bernard, McDermott, David F., Burotto, Mauricio, Choueiri, Toni K., Hammers, Hans J., Plimack, Elizabeth R., Porta, Camillo, George, Saby, Powles, Thomas, Donskov, Frede, Atkins, Michael B., Kollmannsberger, Christian K., Grimm, Marc-Oliver, Tomita, Yoshihiko, Rini, Brian I., Jiang, Ruiyun, Desilva, Heshani, Lee, Chung-Wei, and Motzer, Robert J.

Published
2024
Full Text
View/download PDF

38. Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial.

Author

Bourlon, Maria Teresa, Escudier, Bernard, Burotto, Mauricio, Powles, Thomas, Apolo, Andrea B., Shah, Amishi Yogesh, Porta, Camillo, Suárez, Cristina, Barrios, Carlos H., Richardet, Martin, Gurney, Howard, Kessler, Elizabeth R., Tomita, Yoshihiko, Bedke, Jens, Wang, Fong, Wang, Peter, Panzica, Julie, Fedorov, Viktor, Motzer, Robert J., and Choueiri, Toni K.

Published
2024
Full Text
View/download PDF

40. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

Author

Routy, Bertrand, Le Chatelier, Emmanuelle, Derosa, Lisa, Duong, Connie P. M., Alou, Maryam Tidjani, Daillère, Romain, Fluckiger, Aurélie, Messaoudene, Meriem, Rauber, Conrad, Roberti, Maria P., Fidelle, Marine, Flament, Caroline, Poirier-Colame, Vichnou, Opolon, Paule, Klein, Christophe, Iribarren, Kristina, Mondragón, Laura, Jacquelot, Nicolas, Qu, Bo, Ferrere, Gladys, Clémenson, Céline, Mezquita, Laura, Masip, Jordi Remon, Naltet, Charles, Brosseau, Solenn, Kaderbhai, Coureche, Richard, Corentin, Rizvi, Hira, Levenez, Florence, Galleron, Nathalie, Quinquis, Benoit, Pons, Nicolas, Ryffel, Bernhard, Minard-Colin, Véronique, Gonin, Patrick, Soria, Jean-Charles, Deutsch, Eric, Loriot, Yohann, Ghiringhelli, François, Zalcman, Gérard, Goldwasser, François, Escudier, Bernard, Hellmann, Matthew D., Eggermont, Alexander, Raoult, Didier, Albiges, Laurence, Kroemer, Guido, and Zitvogel, Laurence

Published
2018

46. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial

Author

Schöffski, Patrick, Wozniak, Agnieszka, Escudier, Bernard, Rutkowski, Piotr, Anthoney, Alan, Bauer, Sebastian, Sufliarsky, Jozef, van Herpen, Carla, Lindner, Lars H., Grünwald, Viktor, Zakotnik, Branko, Lerut, Evelyne, Debiec-Rychter, Maria, Marréaud, Sandrine, Lia, Michela, Raveloarivahy, Tiana, Collette, Sandra, and Albiges, Laurence

Published
2017
Full Text
View/download PDF

48. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study

Author

Colomba, Emeline, Le Teuff, Gwénaël, Eisen, Tim, Stewart, Grant D., Fife, Kate, Larkin, James, Biondo, Andrea, Pickering, Lisa, Srinivasan, Anandagopal, Boyle, Helen, Derosa, Lisa, Sternberg, Cora N., Recine, Federica, Ralph, Christy, Saldana, Carolina, Barthélémy, Philippe, Bernhard, Jean Christophe, Gurney, Howard, Verhoest, Gregory, Vauleon, Elodie, Bigot, Pierre, Berger, Julien, Pfister, Christian, Gravis, Gwenaelle, Rodier, Jean-Michel, Culine, Stéphane, Caty, Armelle, Rolland, Frederic, Priou, Franck, Escudier, Bernard, and Albiges, Laurence

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results